Company news

Hunan Fangsheng Pharmaceutical Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Announcement on Soliciting Investor Opinions on Matters Related to 2025 Profit Distribution

February 27, 2026

Announcement on Pledge of Partial Shares of Controlling Shareholder

February 11, 2026

Announcement on Its Holding Subsidiary Obtaining the Drug Production License

February 5, 2026

Announcement on Obtainment of the "Drug Registration Certificate" for Loxoprofen Sodium Cataplasm

January 25, 2026

Announcement on Re-recognition of Wholly-owned Subsidiaries as High-tech Enterprises

January 22, 2026

Announcement on the Inspection Results of the Company's Transfer of Raw Material Production

January 11, 2026

Announcement on Special Dividend in 2025

January 5, 2026

Announcement on Outline of Investor Reception Day

December 21, 2025

Announcement on Subsidiary's Passing GMP Compliance Inspection for Drugs

December 16, 2025

Announcement on Resolutions of the 6th Extraordinary Meeting of the 6th Board of Directors in 2025

December 15, 2025

Announcement on Holding Investor Reception Day

December 12, 2025

Announcement on Inclusion of Innovative Traditional Chinese Medicine Yangxue Qufeng Zhitong Granules in the National Medical Insurance Catalog (2025)

December 8, 2025

Announcement on Obtainment of the "Drug Registration Certificate" for Indobufen Tablets

November 11, 2025

Announcement on Outline of the Q3 2025 Performance Briefing

October 24, 2025

Report for Q3 2025

October 23, 2025

Announcement on Change of ""Drug Manufacturing License"

October 21, 2025

Announcement on Convening the Q3 2025 Performance Briefing

October 16, 2025

Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Subsidiary

October 15, 2025

Announcement on Drug Marketing Authorization Transfer

October 9, 2025

Announcement on Obtaining Summary Report of Phase II Clinical Trial for Zhilong Tongluo Tablets

September 23, 2025

Announcement on Implementation of Semi-annual Dividend Distribution for 2025

September 11, 2025

Announcement on Obtaining Notice of Approval for Drug Clinical Trials by A Holding Subsidiary for Traditional Chinese Medicine Innovative Drug Research Project

September 4, 2025

Announcement on Outline of the 2025 Semi-annual Performance Briefing

August 29, 2025

2025 Semi-annual Report

August 28, 2025

Announcement on Progress in the Sale of Partial Equity in Investment Projects by the M&A Fund Participated and Established by the Company

August 25, 2025

Announcement on Convening the 2025 Semi-annual Performance Briefing

August 21, 2025

Announcement on Providing Non-financing Guarantee for Holding Subsidiary

August 19, 2025

Announcement on Progress in Matters Related to Actual Controller

August 7, 2025

Announcement on Progress in Acquiring Pharmaceutical Production Technology

July 22, 2025

Announcement on Obtaining Notice of Approval for Drug Clinical Trials by Subsidiary for Traditional Chinese Medicine Innovative Drug Research Project

July 11, 2025

Announcement on Progress of Drug Marketing Authorization Transfer

June 20, 2025

Announcement on Obtaining Drug Registration Certificate for Innovative Traditional Chinese Medicine Yangxue Qufeng Zhitong Granules

June 9, 2025

Announcement on Capital Increase to Holding Subsidiary and Related Party Transactions

June 3, 2025

Announcement on Implementation of Dividend Distribution for 2024

June 2, 2025

Announcement on the Progress of Transferring Partial Equity of Holding Subsidiaries and Introducing Strategic Investors

May 21, 2025

Announcement on Resolution of the 2024 Annual General Meeting

May 20, 2025

Announcement on Results of Share Increase by Persons Acting in Concert with Controlling Shareholder

May 14, 2025

Announcement on the Implementation of Repurchase and Cancellation of Equity Incentive Restricted Stock

May 12, 2025

Announcement on Resolutions of the 3rd Extraordinary Meeting of the 6th Board of Supervisors in 2025

May 8, 2025

← Newer news releases